A Randomised, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer

Trial Profile

A Randomised, Double-Blind, Phase III Study to Compare the Efficacy and Safety of Cediranib (AZD2171, RECENTIN) When Added to 5 Fluorouracil, Leucovorin and Oxaliplatin (FOLFOX) or Capecitabine and Oxaliplatin (XELOX) With the Efficacy and Safety of Placebo When Added to FOLFOX or XELOX in Patients With Previously Untreated Metastatic Colorectal Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Cediranib (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZON-II
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Dec 2016 This trial was completed in Czech Republic (end date: 2016-08-17), according to European Clinical Trials Database.
    • 07 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top